Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This is a randomized controlled study of non-damaging photothermal macular grid laser versus sham laser therapy in patients with dry age-related macular degeneration (AMD) and large high-risk drusen. The goal of the study is to determine if this treatment will reduce macular drusen volume and also whether this might improve visual acuity or reduce the risk of conversion to advanced age-related macular degeneration defined as development of choroidal neovascularization or geographic atrophy.

Official Title

Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration

Eligibility Criteria

Ages Eligible for Study: Older than 60 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Exclusion Criteria:
  1. 1. Presence of signs of advanced AMD, such as CNV, haemorrhages or macular atrophy based on OCT and fundus autofluorescence photography (FAF). 2. Previous macular laser treatment. 3. Any previous ocular condition that may be associated with a risk of developing macular oedema. 4. Vitreomacular traction determined clinically and /or by OCT, which in the opinion of the investigator, contributes to the macular oedema (associated or causing a detachment of the fovea). 5. Presence of other macular disease such as epiretinal membrane, macular telangiectasia. 6. Important known allergies to sodium fluorescein dye used in angiography. 7. Ocular or periocular infections. 8. Planned intra-ocular surgery within one year. 9. Patient is unavailable for follow-up visits.


Steven Sanislo, MD
Steven Sanislo, MD
Clinical Professor, Ophthalmology

Contact us to find out if this trial is right for you.


Mariana Nunez